The Drug Enforcement Administration (DEA) recently announced at its 2023 Supply Chain Conference in Houston, Texas, that it would soon announce new rules on synthetic cannabinoids.
Terrence Booth, director of the DEA’s Division of Drug and Chemical Evaluations, spoke about the emerging trend at the May 4 conference. Booth confirmed that the DEA has received “multiple petitions” regarding synthetic cannabinoids and is currently reviewing them. Its regulations reflect recommendations from the US Department of Health and Human Services (HHS).
Booth’s PowerPoint presentation covered topics ranging from drug rescheduling, the operation of counterfeit pills and online drug trafficking. One section was devoted to ‘his decade of dealing with harm’ and covered the evolution of his drugs, including designer spice/bath salts, synthetic opioids, designer benzodiazepines and synthetic cannabinoids ‘CBD to delta 8 THC’. rice field.
“The proposed rule would treat synthetic CBD containing less than 0.1% delta-9-THC the same as AIA,” Booth noted. [agriculture improvement act] This could hint at plans to postpone the schedule for synthetic CBD.
The presentation also covered a brief history of Delta 8 THC, including where it comes from, how it is produced, which states are banning or regulating it, and data representing the growth of Delta 8 products in 2021 and 2022. Delta-8 THC has been found to only occur naturally in cannabis in very limited amounts, and most Delta-8 THC products are made through a chemical process that converts his CBD to Delta-8 THC. I explained that “The act of ingesting the substance at the synthetic stage, in turn, brings it back under the law.” [controlled substances act]” said Booth.
Booth acknowledged that new rules, yet to be published, could change the classification of hemp-derived cannabinoids.
A quick analysis by Vicente LLP suggests that new rules may be introduced soon. “It is important that companies continue to remain involved in current federal schedule activities on marijuana and hemp that impact the legality of cannabis products.” Written by Vicente LLP on that website. “The FDA and DEA are now poised to implement schedule reforms for both marijuana and cannabis, and important congressional bills such as the 2023 Farm Bill could also change the legal classification of certain cannabis products. there is.”
“We expect the DEA to consider the HHS recommendation, develop its own analysis, and eventually publish in the Federal Register a proposed rule that tracks the FDA’s recommendation.” Written by Vicente LLP on that website. “At that point, there will be a public comment period and an opportunity for interested parties to request a hearing on record. Our best guess is that the proposed rule will be published in the Federal Register this fall. It is to be done.”
In February, the DEA released a letter stating that delta-9-THCO and delta-8-THCO are considered controlled substances, not hemp. “Delta-9-THCO and delta-8-THCO do not meet the definition of hemp because they do not occur naturally in the cannabis plant and are only available synthetically,” Booth wrote in the letter. .
Last October, the Food and Drug Administration (FDA) held a webinar called .Understand the FDA’s approach to cannabis science, policy and regulationDuring the discussion, FDA Chief Deputy Commissioner Janet Woodcock said the FDA uses information provided by the National Institute on Drug Abuse (NIDA) to administer “scientific and medical evaluations” of cannabis. explained that “We are committed to looking at marijuana schedules under the Controlled Substances Act and what flexibility we have here.” said the woodcock.. “This is a very high priority that the Secretary of Health is very concerned about. We are also working closely with our NIDA partners and the Assistant Secretary of Health. [HHS]”
But Woodcock acknowledged that the DEA “has the final say” on decisions about scheduling substances. She added that the restrictions make it “very difficult” to study cannabis under the protocols that currently exist.